Boca Raton, FL — December 8, 2025 — Leads & Copy — LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) is expanding from a pure biotech company into a multi-layered oncology platform, following its acquisition of Liora Technologies.
The acquisition brings Liora Technologies’ radiotherapy system, known as the LiGHT System, into LIXTE’s portfolio. The LiGHT system has a smaller physical footprint, lower infrastructure cost, and an adaptable design.
The LiGHT System brings technical advantages that align with modern oncology needs. Proton therapy has long been recognized for its precision, but cost, facility requirements, and the scale of traditional systems have limited adoption. Liora’s technology intends to shift that equation.
LIXTE’s first-in-class PP2A inhibitor, LB-100, is known for disrupting a key cellular checkpoint cancer relies on for survival. By blocking PP2A’s protective signaling, LB-100 removes the tumor’s ability to recover from stress, including the damage caused by radiation. LIXTE can now explore drug-device combinations, design trials pairing LB-100 with proton therapy, and generate insights that would otherwise require extensive collaboration across separate organizations. It brings both halves of a potential combined therapy under one roof, allowing ideas to move more directly from concept to clinical evaluation.
The company is advancing through collaborations with major pharmaceutical companies and a radiotherapy platform positioned for potential adoption in treatment centers.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients. At the core of the Company’s therapy is LB-100, the Company’s proprietary compound that acts as an inhibitor of the PP2A phosphatase with a favorable toxicity profile. LB-100 promotes the production of neoantigens and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes. The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. LIXTE’s unique approach has no known competitors and is covered by a comprehensive patent portfolio.
Media contact for this content: info@hawkpointmedia.com
Source: Lixte Biotechnology Holdings, Inc.
